Keywords: Biocon, CIMAB, Monoclonal antibodies, Biosimilars

India’s Biocon takes over full control of JV with Cuba’s CIMAB

Article | 07 April 2010

Print This

Bangalore, India-based Biocon says that its subsidiary company Biocon SA, has entered into a definitive agreement to acquire the 49% equity ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in